{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:36Z","timestamp":1792802076217,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM","id":[{"id":"https:\/\/ror.org\/05f82e368","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>\n                    Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans. We analyzed tecovirimat antiviral activity on viral kinetics in NHP to characterize its concentration\u2013effect relationship in vivo. Next, we used a pharmacological model developed in healthy volunteers to project its antiviral efficacy in humans. Finally, a viral dynamic model was applied to characterize mpox kinetics in skin lesions from 54 untreated patients, and we used this modeling framework to predict the impact of tecovirimat on viral clearance in skin lesions. At human-recommended doses, tecovirimat could inhibit viral replication from infected cells by more than 90% after 3 to 5 days of drug administration and achieved over 97% efficacy at drug steady state. With an estimated mpox within-host basic reproduction number, R\n                    <jats:sub>0<\/jats:sub>\n                    , equal to 5.6, tecovirimat could therefore shorten the time to viral clearance if given before viral peak. We predicted that initiating treatment at symptom onset, which on average occurred 2 days before viral peak, could reduce the time to viral clearance by about 6 days. Immediate postexposure prophylaxis could not only reduce time to clearance but also lower peak viral load by more than 1.0 log\n                    <jats:sub>10<\/jats:sub>\n                    copies\/mL and shorten the duration of positive viral culture by about 7 to 10 days. These findings support the early administration of tecovirimat against mpox infection, ideally starting from the infection day as a postexposure prophylaxis.\n                  <\/jats:p>","DOI":"10.1371\/journal.pbio.3002249","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:25:09Z","timestamp":1703165109000},"page":"e3002249","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1833","authenticated-orcid":true,"given":"Bach Tran","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Su\u00f1er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ubals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Movie Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mitj\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Grosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"pbio.3002249.ref001","unstructured":"WHO. Multi-country outbreak of mpox, External situation report #19\u201330 March 2023. [cited 2023 Apr 5]. Available from: https:\/\/www.who.int\/publications\/m\/item\/multi-country-outbreak-of-mpox\u2014external-situation-report\u201419\u201430-march-2023."},{"key":"pbio.3002249.ref002","first-page":"14","article-title":"Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation","author":"J Kaler","year":"2022","journal-title":"Cureus"},{"key":"pbio.3002249.ref003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41392-022-01215-4","article-title":"Monkeypox: epidemiology, pathogenesis, treatment and prevention","volume":"7","author":"Y Huang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"pbio.3002249.ref004","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"H Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pbio.3002249.ref005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1473-3099(22)00586-2","article-title":"Viral loads in clinical samples of men with monkeypox virus infection: a French case series","volume":"23","author":"R Palich","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"pbio.3002249.ref006","doi-asserted-by":"crossref","first-page":"e0010384","DOI":"10.1371\/journal.pntd.0010384","article-title":"Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo","volume":"17","author":"PR Pittman","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pbio.3002249.ref007","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(22)00794-0","article-title":"Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain","volume":"23","author":"C Su\u00f1er","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pbio.3002249.ref008","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"G Yang","year":"2005","journal-title":"J Virol"},{"key":"pbio.3002249.ref009","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14787210.2020.1819791","article-title":"An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications","volume":"19","author":"AT Russo","year":"2021","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"pbio.3002249.ref010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral Tecovirimat for the Treatment of Smallpox","volume":"379","author":"DW Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"pbio.3002249.ref011","doi-asserted-by":"crossref","first-page":"e0122622","DOI":"10.1128\/aac.01226-22","article-title":"New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus","volume":"66","author":"CE DeLaurentis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"pbio.3002249.ref012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14787210.2023.2170350","article-title":"Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential","volume":"21","author":"AT Russo","year":"2023","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"pbio.3002249.ref013","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series","volume":"401","author":"O Mitj\u00e0","year":"2023","journal-title":"Lancet"},{"key":"pbio.3002249.ref014","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.00959-12","article-title":"Pharmacokinetic and Pharmacodynamic Modeling To Determine the Dose of ST-246 To Protect against Smallpox in Humans","volume":"57","author":"JM Leeds","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pbio.3002249.ref015","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"J Virol"},{"key":"pbio.3002249.ref016","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"AS Perelson","year":"1996","journal-title":"Science"},{"key":"pbio.3002249.ref017","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"K Best","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002249.ref018","doi-asserted-by":"crossref","first-page":"e2017962118","DOI":"10.1073\/pnas.2017962118","article-title":"Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort","volume":"118","author":"N N\u00e9ant","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002249.ref019","article-title":"Clinical presentation, viral kinetics and management of human monkeypox cases from New Delhi, India 2022","author":"V Relhan","year":"2022","journal-title":"J Med Virol"},{"issue":"5","key":"pbio.3002249.ref020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(23)00214-1","article-title":"Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpox","volume":"23","author":"M Tempestilli","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"pbio.3002249.ref021","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41564-022-01269-8","article-title":"Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations","volume":"7","author":"G Frenois-Veyrat","year":"2022","journal-title":"Nat Microbiol"},{"key":"pbio.3002249.ref022","unstructured":"Drug Approval Package: TPOXX (tecovirimat). U.S. Food And Drug Administration [Internet]. [cited 2023 Apr 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208627Orig1s000PharmR.pdf"},{"key":"pbio.3002249.ref023","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification","volume":"53","author":"R Jordan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"pbio.3002249.ref024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41564-022-01105-z","article-title":"Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness","volume":"7","author":"R Ke","year":"2022","journal-title":"Nat Microbiol"},{"key":"pbio.3002249.ref025","doi-asserted-by":"crossref","first-page":"e75427","DOI":"10.7554\/eLife.75427","article-title":"Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection","volume":"11","author":"M Alexandre","year":"2022","journal-title":"elife"},{"key":"pbio.3002249.ref026","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7861\/clinmed.2022-cme-mpox","article-title":"Human monkeypox infection","volume":"22","author":"A Daunt","year":"2022","journal-title":"Clin Med"},{"key":"pbio.3002249.ref027","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-065X.2008.00691.x","article-title":"Monkeypox virus and insights into its immunomodulatory proteins","volume":"225","author":"JR Weaver","year":"2008","journal-title":"Immunol Rev"},{"key":"pbio.3002249.ref028","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1523-1747.ep12541516","article-title":"Counting and Sizing of Epidermal Cells in Normal Human Skin","volume":"70","author":"PR Bergstresser","year":"1978","journal-title":"J Investig Dermatol"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:25:56Z","timestamp":1703165156000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002249"}},"subtitle":[],"editor":[{"given":"Roland R.","family":"Regoes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3002249","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}